organization · Reporting owner

TANG CAPITAL PARTNERS LP

Disclosed activity across 9 companies

Tapewire entity: 82742
SEC CIK: 0001191935

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Bio Green Med Solution, Inc.CYCC · Entity 8225	10% owner	February 23, 2017	February 27, 2017
HERON THERAPEUTICS, INC. /DE/HRTX · Entity 7133	10% owner	September 12, 2018	September 12, 2018
Jounce Therapeutics, Inc.JNCE · Entity 15754	10% owner	May 03, 2023	May 05, 2023
Odonate Therapeutics, Inc.ODT · Entity 132524	10% owner	November 17, 2021	November 19, 2021

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Bio Green Med Solution, Inc.

Report date February 23, 2017 · Filed February 27, 2017

Jointly reported with TANG KEVIN, TANG CAPITAL MANAGEMENT LLC

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy LP	559,900	Reported balance After 2017-02-23 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2017-02-23 · Purchase · Acquired 134,200 · Balance 559,900 F1: This transaction was executed in multiple trades at prices ranging from $4.09 to $4.50. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2: The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin C. Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP. Mr. Tang disclaims beneficial ownership of the securities, except to the extent of his pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: This transaction was executed in multiple trades at prices ranging from $4.09 to $4.50. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F2: The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin C. Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP. Mr. Tang disclaims beneficial ownership of the securities, except to the extent of his pecuniary interest therein.

HERON THERAPEUTICS, INC. /DE/

Report date September 12, 2018 · Filed September 12, 2018

Jointly reported with TANG KEVIN, TANG CAPITAL MANAGEMENT LLC

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy LP	5,830,215	Reported balance After 2018-09-12 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2018-09-12 · Sale · Disposed 2,695,000 · Balance 5,830,215 F1: The Reporting Person's sale of common stock reported herein may be deemed to be matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, to the extent of 192,308 shares of common stock purchased by the Reporting Person on March 29, 2018. The Reporting Person has sent to the Issuer the full amount of the disgorgeable profit arising from the sale reported herein. F2: The securities are held by Tang Capital Partners, LP. Kevin C. Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of Tang Capital Partners, LP.
Common StockSEC Table I · non-derivative	IndirectAs Trustee	14,347	Reported balance Holding disclosure · report date 2018-09-12 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 14,347 F3: The securities are held by Kevin C. Tang as custodian for his minor children, as Trustee of the Kevin C. Tang Family Trust, and as Trustee of the Tang Advisors, LLC Profit Sharing Plan.
Common StockSEC Table I · non-derivative	Direct	6,941	Reported balance Holding disclosure · report date 2018-09-12 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 6,941 F4: 2,147 of these securities are held by Kevin C. Tang's IRA.

Filing footnotes · ownership attribution and instrument terms

F1: The Reporting Person's sale of common stock reported herein may be deemed to be matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, to the extent of 192,308 shares of common stock purchased by the Reporting Person on March 29, 2018. The Reporting Person has sent to the Issuer the full amount of the disgorgeable profit arising from the sale reported herein.

F2: The securities are held by Tang Capital Partners, LP. Kevin C. Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of Tang Capital Partners, LP.

F3: The securities are held by Kevin C. Tang as custodian for his minor children, as Trustee of the Kevin C. Tang Family Trust, and as Trustee of the Tang Advisors, LLC Profit Sharing Plan.

F4: 2,147 of these securities are held by Kevin C. Tang's IRA.

Jounce Therapeutics, Inc.

Report date May 03, 2023 · Filed May 05, 2023

Jointly reported with TANG KEVIN, TANG CAPITAL MANAGEMENT LLC

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy LP	0	Reported balance After 2023-05-03 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2023-05-03 · Other · Disposed 5,300,087 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 26, 2023, by and among the Issuer, Concentra Biosciences, LLC, ("Concentra"), and Concentra Merger Sub, Inc., a wholly-owned subsidiary of Concentra ("Merger Sub"), to which Concentra completed a tender offer (the "Offer") for shares of common stock of the Issuer, $0.001 par value per share (each, a "Share"), and thereafter merged with and into the Issuer (the "Merger") effective as of May 3, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was converted into the right to receive $1.85 per Share (the "Cash Consideration") plus one non-transferable contractual contingent value right per Share (each, a "CVR," and each CVR together with the Cash Consideration, the "Offer Price"). From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled. F2: The Reporting Person has delivered to the Issuer the full amount of the disgorgeable profit arising the sale reported herein, in the amount of $73,118.01. F3: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP.
Common StockSEC Table I · non-derivative	IndirectBy LP	10,000	Reported balance After 2023-05-03 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2023-05-03 · Other · Acquired 10,000 · Balance 10,000 F4: On May 3, 2023, the Offer expired and Merger Sub accepted for purchase a total of 36,367,727 shares tendered and not withdrawn, representing approximately 69.0926% of the total shares of the Issuer issued and outstanding. Following the expiration of the Offer, Merger Sub merged with and into the Issuer on May 3, 2023, pursuant to Section 251(h) of the Delaware General Corporation Law, and, among other things, each share of common stock of Merger Sub issued and outstanding immediately before the Effective Time automatically converted into and became one validly issued, fully paid and non-assessable share of common stock, par value $0.0001 per share, of the Issuer (representing 10,000 shares in the aggregate), with the Issuer surviving as a wholly owned subsidiary of Concentra. As a result of the Offer and the Merger, Concentra acquired a total of 10,000 shares of Common Stock in exchange for $97,377,034.75 in cash and 60,142,813 CVRs. F5: The shares are beneficially owned by Concentra. Concentra is wholly owned by TCP. Kevin Tang is the sole manager of TCM, which is the general partner of TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by Concentra.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 26, 2023, by and among the Issuer, Concentra Biosciences, LLC, ("Concentra"), and Concentra Merger Sub, Inc., a wholly-owned subsidiary of Concentra ("Merger Sub"), to which Concentra completed a tender offer (the "Offer") for shares of common stock of the Issuer, $0.001 par value per share (each, a "Share"), and thereafter merged with and into the Issuer (the "Merger") effective as of May 3, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was converted into the right to receive $1.85 per Share (the "Cash Consideration") plus one non-transferable contractual contingent value right per Share (each, a "CVR," and each CVR together with the Cash Consideration, the "Offer Price"). From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled.

F2: The Reporting Person has delivered to the Issuer the full amount of the disgorgeable profit arising the sale reported herein, in the amount of $73,118.01.

F3: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP.

F4: On May 3, 2023, the Offer expired and Merger Sub accepted for purchase a total of 36,367,727 shares tendered and not withdrawn, representing approximately 69.0926% of the total shares of the Issuer issued and outstanding. Following the expiration of the Offer, Merger Sub merged with and into the Issuer on May 3, 2023, pursuant to Section 251(h) of the Delaware General Corporation Law, and, among other things, each share of common stock of Merger Sub issued and outstanding immediately before the Effective Time automatically converted into and became one validly issued, fully paid and non-assessable share of common stock, par value $0.0001 per share, of the Issuer (representing 10,000 shares in the aggregate), with the Issuer surviving as a wholly owned subsidiary of Concentra. As a result of the Offer and the Merger, Concentra acquired a total of 10,000 shares of Common Stock in exchange for $97,377,034.75 in cash and 60,142,813 CVRs.

F5: The shares are beneficially owned by Concentra. Concentra is wholly owned by TCP. Kevin Tang is the sole manager of TCM, which is the general partner of TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by Concentra.

Odonate Therapeutics, Inc.

Report date November 17, 2021 · Filed November 19, 2021

Jointly reported with TANG KEVIN, TANG CAPITAL MANAGEMENT LLC, Hearne Michael S

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy LP	12,767,435	Last balance in matching sequence After 2021-11-19 transaction · row 8 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 8 source rows Row 1 · 2021-11-17 · Sale · Disposed 468,849 · Balance 15,045,717 F1: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $2.01 to $3.01. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC Staff, upon request, full information regarding the number of shares sold at each price within the ranges set forth in footnotes 1 and 3 through 9 herein. F2: The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of common stock that are held of record by Odonate Holdings, LLC ("Holdings"). Holdings has granted a proxy to TCP giving TCP the sole authority to vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP. Row 2 · 2021-11-17 · Sale · Disposed 31,151 · Balance 15,014,566 F3: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $1.99 to $2.005. F2: The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of common stock that are held of record by Odonate Holdings, LLC ("Holdings"). Holdings has granted a proxy to TCP giving TCP the sole authority to vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP. Row 3 · 2021-11-17 · Sale · Disposed 500,000 · Balance 14,514,566 F4: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $1.95 to $2.07. F2: The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of common stock that are held of record by Odonate Holdings, LLC ("Holdings"). Holdings has granted a proxy to TCP giving TCP the sole authority to vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP. Row 4 · 2021-11-17 · Sale · Disposed 287,577 · Balance 14,226,989 F5: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $2.10 to $2.33. F2: The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of common stock that are held of record by Odonate Holdings, LLC ("Holdings"). Holdings has granted a proxy to TCP giving TCP the sole authority to vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP. Row 5 · 2021-11-18 · Sale · Disposed 212,423 · Balance 14,014,566 F6: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $1.91 to $2.16. F2: The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of common stock that are held of record by Odonate Holdings, LLC ("Holdings"). Holdings has granted a proxy to TCP giving TCP the sole authority to vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP. Row 6 · 2021-11-18 · Sale · Disposed 500,000 · Balance 13,514,566 F7: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $1.85 to $1.99. F2: The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of common stock that are held of record by Odonate Holdings, LLC ("Holdings"). Holdings has granted a proxy to TCP giving TCP the sole authority to vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP. Row 7 · 2021-11-18 · Sale · Disposed 381,842 · Balance 13,132,724 F8: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $1.85 to $2.001. F2: The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of common stock that are held of record by Odonate Holdings, LLC ("Holdings"). Holdings has granted a proxy to TCP giving TCP the sole authority to vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP. Row 8 · 2021-11-19 · Sale · Disposed 365,289 · Balance 12,767,435 F9: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $1.85 to $1.985. F2: The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of common stock that are held of record by Odonate Holdings, LLC ("Holdings"). Holdings has granted a proxy to TCP giving TCP the sole authority to vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP.

Filing footnotes · ownership attribution and instrument terms

F1: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $2.01 to $3.01. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC Staff, upon request, full information regarding the number of shares sold at each price within the ranges set forth in footnotes 1 and 3 through 9 herein.

F2: The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of common stock that are held of record by Odonate Holdings, LLC ("Holdings"). Holdings has granted a proxy to TCP giving TCP the sole authority to vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP.

F3: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $1.99 to $2.005.

F4: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $1.95 to $2.07.

F5: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $2.10 to $2.33.

F6: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $1.91 to $2.16.

F7: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $1.85 to $1.99.

F8: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $1.85 to $2.001.

F9: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $1.85 to $1.985.

Past disclosures · reporting ended (5)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Aptevo Therapeutics Inc.

Report date November 23, 2021 · Filed November 26, 2021

Jointly reported with TANG KEVIN, TANG CAPITAL MANAGEMENT LLC

Section 16 reporting ended · disclosed 2021-11-26. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy LP	0	Last balance in matching sequence After 2021-11-23 transaction · row 7 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 7 source rows Row 1 · 2021-11-23 · Sale · Disposed 161,336 · Balance 760,000 F1: The prices reported in Column 4 are weighted average prices. These shares were sold in multiple transactions at prices ranging from $13.29 to $13.77. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC Staff, upon request, full information regarding the number of shares sold at each price within the ranges set forth in footnotes 1 and 3 through 8 herein. F2: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP. Row 2 · 2021-11-23 · Sale · Disposed 124,509 · Balance 635,491 F3: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $11.97 to $12.90. F2: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP. Row 3 · 2021-11-23 · Sale · Disposed 75,491 · Balance 560,000 F4: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $11.59 to $11.89. F2: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP. Row 4 · 2021-11-23 · Sale · Disposed 149,111 · Balance 410,889 F5: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $10.74 to $11.67. F2: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP. Row 5 · 2021-11-23 · Sale · Disposed 50,889 · Balance 360,000 F6: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $10.31 to $10.64. F2: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP. Row 6 · 2021-11-23 · Sale · Disposed 200,000 · Balance 160,000 F7: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $9.59 to $10.34. F2: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP. Row 7 · 2021-11-23 · Sale · Disposed 160,000 · Balance 0 F8: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $9.50 to $10.20. F2: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP.

Filing footnotes · ownership attribution and instrument terms

F1: The prices reported in Column 4 are weighted average prices. These shares were sold in multiple transactions at prices ranging from $13.29 to $13.77. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC Staff, upon request, full information regarding the number of shares sold at each price within the ranges set forth in footnotes 1 and 3 through 8 herein.

F3: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $11.97 to $12.90.

F4: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $11.59 to $11.89.

F5: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $10.74 to $11.67.

F6: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $10.31 to $10.64.

F7: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $9.59 to $10.34.

F8: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $9.50 to $10.20.

LA JOLLA PHARMACEUTICAL CO

Report date August 22, 2022 · Filed August 24, 2022

Jointly reported with TANG KEVIN, TANG CAPITAL MANAGEMENT LLC, Hearne Michael S

Section 16 reporting ended · disclosed 2022-08-24. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy LP	0	Reported balance After 2022-08-22 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2022-08-22 · Other · Disposed 9,607,934 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation ("Parent"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of the Parent ("Purchaser"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a "Share"), and thereafter merged with and into the Issuer (the "Merger") effective as of August 22, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was converted into the right to receive $6.23 per Share, in cash, without interest (the "Offer Price") and subject to any withholding of taxes, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled. F2: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in the shares beneficially held by TCP.
Series C-1(2) Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectBy LP	0	Reported balance After 2022-08-22 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2022-08-22 · Other · Disposed 3,519.315 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each share of Series C-1(2) Convertible Preferred Stock was converted into the right to receive an amount in cash equal to 1,724.04 times the Offer Price. F2: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in the shares beneficially held by TCP.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation ("Parent"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of the Parent ("Purchaser"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a "Share"), and thereafter merged with and into the Issuer (the "Merger") effective as of August 22, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was converted into the right to receive $6.23 per Share, in cash, without interest (the "Offer Price") and subject to any withholding of taxes, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled.

F2: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in the shares beneficially held by TCP.

F3: Pursuant to the Merger Agreement, at the Effective Time, each share of Series C-1(2) Convertible Preferred Stock was converted into the right to receive an amount in cash equal to 1,724.04 times the Offer Price.

Rain Oncology Inc.

Report date January 26, 2024 · Filed February 02, 2024

Jointly reported with TANG KEVIN, TANG CAPITAL MANAGEMENT LLC

Section 16 reporting ended · disclosed 2024-02-02. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy LP	0	Reported balance After 2024-01-26 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2024-01-26 · Other · Disposed 3,850,513 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of December 13, 2023, by and among the Issuer, Pathos AI, Inc. ("Parent"), and WK Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Parent, to which Parent completed a tender offer for shares of common stock of the Issuer, $0.001 par value per share (each, a "Share"), and thereafter merged with and into the Issuer effective as of January 26, 2024 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was converted into the right to receive $1.16 per Share plus one contingent value right for potential cash payments of up to approximately $0.17 per Share. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled. F2: The Reporting Person has delivered to the Issuer the full amount of the disgorgeable profit arising the sale reported herein, in the amount of $18,729.24. F3: The Reporting Persons received the following in exchange for each Share tendered in connection with the Merger: $1.16 in cash per Share and one contingent value right for potential cash payments of up to approximately $0.17 per Share. F4: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of December 13, 2023, by and among the Issuer, Pathos AI, Inc. ("Parent"), and WK Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Parent, to which Parent completed a tender offer for shares of common stock of the Issuer, $0.001 par value per share (each, a "Share"), and thereafter merged with and into the Issuer effective as of January 26, 2024 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was converted into the right to receive $1.16 per Share plus one contingent value right for potential cash payments of up to approximately $0.17 per Share. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled.

F2: The Reporting Person has delivered to the Issuer the full amount of the disgorgeable profit arising the sale reported herein, in the amount of $18,729.24.

F3: The Reporting Persons received the following in exchange for each Share tendered in connection with the Merger: $1.16 in cash per Share and one contingent value right for potential cash payments of up to approximately $0.17 per Share.

F4: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP.

Singular Genomics Systems, Inc.

Report date February 21, 2025 · Filed February 28, 2025

Jointly reported with TANG KEVIN, TANG CAPITAL MANAGEMENT LLC

Section 16 reporting ended · disclosed 2025-02-28. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy LP	0	Reported balance After 2025-02-21 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2025-02-21 · Disposition to issuer · Disposed 372,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of December 22, 2024, by and among Singular Genomics Systems, Inc. (the "Issuer"), Singular Genomics Parent, LLC, a Delaware limited liability company, and Saturn Merger Sub, Inc., a Delaware corporation, whereby, at the effective time of the merger contemplated therein, all issued and outstanding shares of Issuer common stock were cancelled and automatically converted into the right to receive $20.00 per share in cash, without interest, less all applicable deductions and withholdings. F2: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of December 22, 2024, by and among Singular Genomics Systems, Inc. (the "Issuer"), Singular Genomics Parent, LLC, a Delaware limited liability company, and Saturn Merger Sub, Inc., a Delaware corporation, whereby, at the effective time of the merger contemplated therein, all issued and outstanding shares of Issuer common stock were cancelled and automatically converted into the right to receive $20.00 per share in cash, without interest, less all applicable deductions and withholdings.

F2: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP.

TCR2 THERAPEUTICS INC.

Report date June 01, 2023 · Filed February 14, 2024

Jointly reported with TANG KEVIN, TANG CAPITAL MANAGEMENT LLC

Section 16 reporting ended · disclosed 2024-02-14. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy LP	0	Reported balance After 2023-06-01 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2023-06-01 · Other · Disposed 4,394,800 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, by and among TCR2 Therapeutics, Inc. (the "Issuer"), Adaptimmune Therapeutics plc ("Parent"), and CM Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Parent ("Merger Sub"), as amended by Amendment No. 1 to the Agreement and Plan of Merger, dated April 5, 2023, by and among the Issuer, Parent, and Merger Sub, to which Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as an indirect wholly-owned subsidiary of Parent effective as of June 1, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a "Share") was cancelled and converted into the right to receive 1.5117 American Depository Shares of Parent ("Parent ADS"), representing six ordinary shares of Parent. F2: The Reporting Persons received 1.5117 Parent ADSs in exchange for each Share cancelled in connection with the Merger. F3: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, by and among TCR2 Therapeutics, Inc. (the "Issuer"), Adaptimmune Therapeutics plc ("Parent"), and CM Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Parent ("Merger Sub"), as amended by Amendment No. 1 to the Agreement and Plan of Merger, dated April 5, 2023, by and among the Issuer, Parent, and Merger Sub, to which Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as an indirect wholly-owned subsidiary of Parent effective as of June 1, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a "Share") was cancelled and converted into the right to receive 1.5117 American Depository Shares of Parent ("Parent ADS"), representing six ordinary shares of Parent.

F2: The Reporting Persons received 1.5117 Parent ADSs in exchange for each Share cancelled in connection with the Merger.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
February 16, 2018 Filed Feb 16, 2018 23:47 UTC	Odonate Therapeutics, Inc. ODT · Entity 132524	PurchaseCommon Stock	29,109	$23.72	$690,474.21	Disclosure SEC source: 0001209191-18-011056 · doc4.xml · nonDerivative · entry 3 TANG KEVIN C · CIK 0001178579 · Director · Chief Executive Officer · 10% owner TANG CAPITAL PARTNERS LP · CIK 0001191935 · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner Lemkey John G · CIK 0001495904 · Chief Financial Officer Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By LP Disclosed balance after: 12,302,338 F1 · ownership.direct: The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin C. Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of common stock that are held of record by Odonate Holdings, LLC ("Holdings"). Holdings has granted a proxy to TCP giving TCP the sole authority to vote such shares. John G. Lemkey is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Operating Officer of TCM. Mr. Lemkey has a pecuniary interest in a portion of the shares beneficially held by TCP. Both Mr. Tang and Mr. Lemkey disclaim beneficial ownership of the shares held by TCP, except to the extent of their pecuniary interest therein. F1 · ownership.nature: The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin C. Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of common stock that are held of record by Odonate Holdings, LLC ("Holdings"). Holdings has granted a proxy to TCP giving TCP the sole authority to vote such shares. John G. Lemkey is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Operating Officer of TCM. Mr. Lemkey has a pecuniary interest in a portion of the shares beneficially held by TCP. Both Mr. Tang and Mr. Lemkey disclaim beneficial ownership of the shares held by TCP, except to the extent of their pecuniary interest therein. Read SEC document
February 15, 2018 Filed Feb 16, 2018 23:47 UTC	Odonate Therapeutics, Inc. ODT · Entity 132524	PurchaseCommon Stock	34,943	$21.98	$768,075.09	Disclosure SEC source: 0001209191-18-011056 · doc4.xml · nonDerivative · entry 2 TANG KEVIN C · CIK 0001178579 · Director · Chief Executive Officer · 10% owner TANG CAPITAL PARTNERS LP · CIK 0001191935 · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner Lemkey John G · CIK 0001495904 · Chief Financial Officer Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By LP Disclosed balance after: 12,273,229 F1 · ownership.direct: The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin C. Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of common stock that are held of record by Odonate Holdings, LLC ("Holdings"). Holdings has granted a proxy to TCP giving TCP the sole authority to vote such shares. John G. Lemkey is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Operating Officer of TCM. Mr. Lemkey has a pecuniary interest in a portion of the shares beneficially held by TCP. Both Mr. Tang and Mr. Lemkey disclaim beneficial ownership of the shares held by TCP, except to the extent of their pecuniary interest therein. F1 · ownership.nature: The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin C. Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of common stock that are held of record by Odonate Holdings, LLC ("Holdings"). Holdings has granted a proxy to TCP giving TCP the sole authority to vote such shares. John G. Lemkey is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Operating Officer of TCM. Mr. Lemkey has a pecuniary interest in a portion of the shares beneficially held by TCP. Both Mr. Tang and Mr. Lemkey disclaim beneficial ownership of the shares held by TCP, except to the extent of their pecuniary interest therein. Read SEC document
February 14, 2018 Filed Feb 16, 2018 23:47 UTC	Odonate Therapeutics, Inc. ODT · Entity 132524	PurchaseCommon Stock	35,948	$20.39	$732,821.55	Disclosure SEC source: 0001209191-18-011056 · doc4.xml · nonDerivative · entry 1 TANG KEVIN C · CIK 0001178579 · Director · Chief Executive Officer · 10% owner TANG CAPITAL PARTNERS LP · CIK 0001191935 · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner Lemkey John G · CIK 0001495904 · Chief Financial Officer Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By LP Disclosed balance after: 12,238,286 F1 · ownership.direct: The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin C. Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of common stock that are held of record by Odonate Holdings, LLC ("Holdings"). Holdings has granted a proxy to TCP giving TCP the sole authority to vote such shares. John G. Lemkey is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Operating Officer of TCM. Mr. Lemkey has a pecuniary interest in a portion of the shares beneficially held by TCP. Both Mr. Tang and Mr. Lemkey disclaim beneficial ownership of the shares held by TCP, except to the extent of their pecuniary interest therein. F1 · ownership.nature: The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin C. Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of common stock that are held of record by Odonate Holdings, LLC ("Holdings"). Holdings has granted a proxy to TCP giving TCP the sole authority to vote such shares. John G. Lemkey is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Operating Officer of TCM. Mr. Lemkey has a pecuniary interest in a portion of the shares beneficially held by TCP. Both Mr. Tang and Mr. Lemkey disclaim beneficial ownership of the shares held by TCP, except to the extent of their pecuniary interest therein. Read SEC document
December 07, 2017 Filed Dec 8, 2017 14:15 UTC	Odonate Therapeutics, Inc. ODT · Entity 132524	PurchaseCommon Stock	1,291,666	$24.00	$30,999,984.00	Disclosure SEC source: 0001209191-17-064596 · doc4.xml · nonDerivative · entry 1 TANG KEVIN C · CIK 0001178579 · Director · Chief Executive Officer · 10% owner TANG CAPITAL PARTNERS LP · CIK 0001191935 · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner Lemkey John G · CIK 0001495904 · Chief Financial Officer Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By LP Disclosed balance after: 12,202,338 F1 · ownership.nature: The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin C. Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of common stock that are held of record by Odonate Holdings, LLC ("Holdings"). Holdings has granted a proxy to TCP giving TCP the sole authority to vote such shares. John G. Lemkey is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Operating Officer of TCM. Mr. Lemkey has a pecuniary interest in a portion of the shares beneficially held by TCP. Both Mr. Tang and Mr. Lemkey disclaim beneficial ownership of the shares held by TCP, except to the extent of their pecuniary interest therein. Read SEC document
March 23, 2017 Filed Mar 27, 2017 16:15 UTC	LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310	PurchaseCommon Stock	149,254	$33.50	$5,000,009.00	Disclosure SEC source: 0001209191-17-022939 · doc4.xml · nonDerivative · entry 1 TANG KEVIN C · CIK 0001178579 · Director · 10% owner TANG CAPITAL PARTNERS LP · CIK 0001191935 · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By LP Disclosed balance after: 3,440,419 F1 · ownership.direct: The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin C. Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP. Mr. Tang disclaims beneficial ownership of the securities, except to the extent of his pecuniary interest therein. F1 · ownership.nature: The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin C. Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP. Mr. Tang disclaims beneficial ownership of the securities, except to the extent of his pecuniary interest therein. Read SEC document
March 02, 2017 Filed Mar 6, 2017 16:01 UTC	LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310	PurchaseCommon Stock	100,000	$34.64	$3,463,840.00	Disclosure SEC source: 0001209191-17-018261 · doc4.xml · nonDerivative · entry 1 TANG KEVIN C · CIK 0001178579 · Director · 10% owner TANG CAPITAL PARTNERS LP · CIK 0001191935 · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By LP Disclosed balance after: 3,291,165 F1 · ownership.direct: The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin C. Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP. Mr. Tang disclaims beneficial ownership of the securities, except to the extent of his pecuniary interest therein. F1 · ownership.nature: The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin C. Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP. Mr. Tang disclaims beneficial ownership of the securities, except to the extent of his pecuniary interest therein. Read SEC document
February 23, 2017 Filed Feb 27, 2017 22:10 UTC	Bio Green Med Solution, Inc. CYCC · Entity 8225	PurchaseCommon Stock	134,200	$4.34	$582,079.08	Disclosure SEC source: 0001209191-17-014875 · doc4.xml · nonDerivative · entry 1 TANG KEVIN C · CIK 0001178579 · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner TANG CAPITAL PARTNERS LP · CIK 0001191935 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By LP Disclosed balance after: 559,900 F1 · price: This transaction was executed in multiple trades at prices ranging from $4.09 to $4.50. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.direct: The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin C. Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP. Mr. Tang disclaims beneficial ownership of the securities, except to the extent of his pecuniary interest therein. F2 · ownership.nature: The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin C. Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP. Mr. Tang disclaims beneficial ownership of the securities, except to the extent of his pecuniary interest therein. Read SEC document
January 19, 2017 Filed Jan 23, 2017 21:03 UTC	HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133	PurchaseCommon Stock	2,459,016	$12.20	$29,999,995.20	Disclosure SEC source: 0001209191-17-005068 · doc4.xml · nonDerivative · entry 1 TANG KEVIN C · CIK 0001178579 · Director · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner TANG CAPITAL PARTNERS LP · CIK 0001191935 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By LP Disclosed balance after: 8,332,907 F1 · ownership.direct: The securities are held by Tang Capital Partners, LP and Tang (APPA) Holdings, LLC. Kevin C. Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of Tang Capital Partners, LP. Tang Capital Partners, LP is the sole manager of Tang (APPA) Holdings, LLC. Mr. Tang disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. F1 · ownership.nature: The securities are held by Tang Capital Partners, LP and Tang (APPA) Holdings, LLC. Kevin C. Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of Tang Capital Partners, LP. Tang Capital Partners, LP is the sole manager of Tang (APPA) Holdings, LLC. Mr. Tang disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document
September 13, 2016 Filed Sep 13, 2016 18:42 UTC	LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310	PurchaseCommon Stock	16,448	$20.28	$333,514.45	Disclosure SEC source: 0001209191-16-141290 · doc4.xml · nonDerivative · entry 3 TANG KEVIN C · CIK 0001178579 · Director · 10% owner TANG CAPITAL PARTNERS LP · CIK 0001191935 · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By LP Disclosed balance after: 3,191,165 F1 · ownership.direct: The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin C. Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP. Mr. Tang disclaims beneficial ownership of the securities, except to the extent of his pecuniary interest therein. F1 · ownership.nature: The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin C. Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP. Mr. Tang disclaims beneficial ownership of the securities, except to the extent of his pecuniary interest therein. Read SEC document
September 12, 2016 Filed Sep 13, 2016 18:42 UTC	LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310	PurchaseCommon Stock	22,587	$19.92	$449,885.61	Disclosure SEC source: 0001209191-16-141290 · doc4.xml · nonDerivative · entry 2 TANG KEVIN C · CIK 0001178579 · Director · 10% owner TANG CAPITAL PARTNERS LP · CIK 0001191935 · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By LP Disclosed balance after: 3,174,717 F1 · ownership.direct: The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin C. Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP. Mr. Tang disclaims beneficial ownership of the securities, except to the extent of his pecuniary interest therein. F1 · ownership.nature: The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin C. Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP. Mr. Tang disclaims beneficial ownership of the securities, except to the extent of his pecuniary interest therein. Read SEC document
September 09, 2016 Filed Sep 13, 2016 18:42 UTC	LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310	PurchaseCommon Stock	100,000	$19.72	$1,971,970.00	Disclosure SEC source: 0001209191-16-141290 · doc4.xml · nonDerivative · entry 1 TANG KEVIN C · CIK 0001178579 · Director · 10% owner TANG CAPITAL PARTNERS LP · CIK 0001191935 · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By LP Disclosed balance after: 3,152,130 F1 · ownership.direct: The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin C. Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP. Mr. Tang disclaims beneficial ownership of the securities, except to the extent of his pecuniary interest therein. F1 · ownership.nature: The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin C. Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP. Mr. Tang disclaims beneficial ownership of the securities, except to the extent of his pecuniary interest therein. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.